Entrusted by Daewon Pharm Co., Ltd. of South Korea, our company has been providing import registration agency services and in vitro dissolution profile development for its product "Pelubiprofen Extended-Release Tablets (Specification: 45 mg, Brand name: Pelubi®)." This product has been marketed in South Korea for many years, with indications including relief of symptoms of osteoarthritis, rheumatoid arthritis, and low back pain. Classified as registration Category 5.1, this product represents the first domestic application of its kind. Through the joint efforts of both parties, the Clinical Trial Approval Notice was successfully issued by the National Medical Products Administration (NMPA) on February 11, 2020.